{
  "id": 14193727,
  "title": "Undecimal Bio lands €16 million to develop targeted RNA medicines beyond the liver",
  "url": "https://urgent.news/2026/10/13/undecimal-bio-lands-16-million-to-develop-targeted-rna-medicines",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-13T11:42:51.000Z",
  "source": {
    "name": "EU-Startups",
    "slug": "eu-startups",
    "url": "https://www.eu-startups.com/2026/10/undecimal-bio-lands-e16-million-to-develop-targeted-rna-medicines-beyond-the-liver/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Cambridge-based Undecimal Bio, a spin-out from Eleven Therapeutics advancing targeted delivery of siRNA therapeutics, today announced a €16 million ($18 million) Seed financing round to expand DELiveri, its proprietary AI-enabled platform for identifying conjugates that can direct RNA medicines to defined cell types. The round was co-led by 4BIO Capital and IQ Capital, with participation […] The…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}